Search results for "RAV"

showing 10 items of 5866 documents

P02-358 - Clinical Findings on Computergame Addiction: The Role of Personality, Stress and Coping

2010

IntroductionBehavioral addictions, like computergame addiction respectively internet addiction, have become a growing concern in research. Currently similarities between behavioral addictions and substance dependency are discussed in the scientific community controversially. Unfortunately a mismatch exists between high rates of treatment seeking people and low rates of scientific studies on computergame-addiction, especially concerning risk factors and their contribution to the etiology of computergame addiction.ObjectivesThe aim of this contribution is to shed light on possible etiological factors of computergame addiction concerning personality and vulnerability to stress in clients of th…

medicine.medical_specialtyCoping (psychology)Extraversion and introversionmedia_common.quotation_subjectAddictionConscientiousnessNeuroticismPsychiatry and Mental healthmental disordersmedicinePersonalityOutpatient clinicPsychologyPsychiatryClinical psychologymedia_commonPsychopathologyEuropean Psychiatry
researchProduct

Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study

2016

Aims In patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, treatment with intravenous iron has shown a clinical improvement regardless of anaemic status. Cardiac magnetic resonance (CMR) T2* sequence has shown a potential utility for evaluating myocardial iron deficiency. We aimed to evaluate whether T2* sequence significantly changes after ferric carboximaltose (FCM) administration, and if such changes correlate with changes in left ventricle ejection fraction (LVEF). Methods and results In this pilot study, we included eight patients with chronic symptomatic (New York Heart Association II–III) HFrEF and iron deficiency. A CMR, including T2* analysis, w…

medicine.medical_specialtyEjection fractionmedicine.diagnostic_testbusiness.industryIntravenous ironMagnetic resonance imagingIron deficiency030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureInterquartile rangeVentricleHeart failureInternal medicineCardiologyMedicineIn patient030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessESC Heart Failure
researchProduct

The deltoid muscle: an electromyographical analysis of its activity in arm abduction in various body postures

1992

We have carried out an electromyographical examination of the activity of five different regions of the deltoid muscle during abduction/adduction in various body postures with different biomechanical actions of arm gravity. The results show that the deltoid action is highly differentiated in its different regions and is not restricted only to the generation of an abducting moment in the shoulder joint. There is obviously a biomechanical contribution, mainly by its spinal and clavicular regions, to the stabilization of the glenohumeral joint and to the control of the selected plane of abduction.

medicine.medical_specialtyElectrodiagnosisMovementPostureDeltoid curveElectromyographyBiomechanical PhenomenaPhysical medicine and rehabilitationDeltoid musclemedicineHumansOrthopedics and Sports Medicinemedicine.diagnostic_testElectromyographyBody posturebusiness.industryMusclesAnatomyBiomechanical Phenomenabody regionsmedicine.anatomical_structureArmSurgeryShoulder jointmedicine.symptombusinesshuman activitiesGravitationMuscle ContractionMuscle contractionInternational Orthopaedics
researchProduct

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

2011

Abstract The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection fro…

medicine.medical_specialtyEndotheliummedicine.medical_treatmentlcsh:MedicineInflammationReviewAscorbic AcidMicrobiologyGastroenterologyGeneral Biochemistry Genetics and Molecular BiologySepsisNeoplasmsSepsisInternal medicinemedicineHumansEndotheliumAscorbic Acid DeficiencyCancerImmunology and Infectious DiseaseMedicine(all)Biochemistry Genetics and Molecular Biology(all)business.industrylcsh:RImmunityCancerGeneral Medicinemedicine.diseaseAscorbic acidSystemic inflammatory response syndromemedicine.anatomical_structureOncologyInjections IntravenousImmunologyAscorbic Acid DeficiencyIntravenous ascorbic acidmedicine.symptombusinessAdjuvantJournal of Translational Medicine
researchProduct

The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract

2010

Aliment Pharmacol Ther 31, 548–552 Summary Background  Confocal laser endomicroscopy (CLE) is rapidly emerging as a valuable tool for gastrointestinal endoscopic imaging. Fluorescent contrast agents are used to optimize imaging with CLE, and intravenous fluorescein is the most widely used contrast agent. Fluorescein is FDA-cleared for diagnostic angiography of the retina. For these indications, the safety profile of fluorescein has been well-documented; however, to date, fluorescein is not cleared for use with CLE. Aims  To estimate the rate of serious and total adverse events attributable to intravenous fluorescein when used for gastrointestinal CLE. Methods  We performed a cross sectional…

medicine.medical_specialtyErythemaNauseaGastrointestinal DiseasesVomitingContrast MediaPainEndoscopy Gastrointestinalchemistry.chemical_compoundmedicineHumansPharmacology (medical)FluoresceinAdverse effectGastrointestinal tractMicroscopy ConfocalHepatologymedicine.diagnostic_testbusiness.industryUnited States Food and Drug AdministrationStomachfungiGastroenterologyNauseaExanthemaUnited StatesSurgeryEndoscopymedicine.anatomical_structureCross-Sectional StudieschemistryAnesthesiaInjections IntravenousVomitingFluoresceinmedicine.symptomHypotensionbusinessAlimentary pharmacology & therapeutics
researchProduct

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia

2018

Background: Intravenous immunoglobulin (IVIG) IQYMUNE® is a highly purified 10% IVIG that was assessed using the new stringent definition of response described in the revised guideline on the clinical investigation of IVIG. The efficacy and the safety of IQYMUNE® were investigated in adult patients with chronic primary immune thrombocytopenia (ITP). Methods: In this phase III multinational, multicentre, prospective, uncontrolled, open-label, single-arm study, adult patients with a baseline platelet count < 30 × 10 9 /L were treated with IVIG 10% at a dose of 2 g/kg body weight administered over 2 consecutive days. The primary endpoint was Response over the study period and was defined accor…

medicine.medical_specialtyEuropean Medicines Agency guidelinesPlatelet countRenal functionHigh dose030204 cardiovascular system & hematologyGastroenterology03 medical and health sciencesIntravenous immunoglobulin; High dose; Immune thrombocytopenia; Response; European Medicines Agency guidelines; Platelet count; Bleeding assessment; Infusion rate0302 clinical medicineInfusion rateInternal medicinemedicineClinical endpointPlateletAdverse effectIntravenous immunoglobulinbiologybusiness.industryResponseGuidelineImmune thrombocytopeniaImmune thrombocytopenia030220 oncology & carcinogenesisConcomitantbiology.proteinBleeding assessmentOriginal ArticleAntibodybusinessJournal of Hematology
researchProduct

A 2013 European survey of clinical practice patterns in the management of Graves' disease

2014

SummaryObjective Management of Graves' disease (GD) in Europe was published in 1987. Aim of this survey was to provide an update on clinical practice in Europe, and to compare it with a 2011 American survey. Design Members of the European Thyroid Association (ETA) were asked to participate in a survey on management of GD, using the same questionnaire of a recent American survey. Results A total of 147 ETA members participated. In addition to serum TSH and free T4 assays, most respondents would request TSH-receptor autoantibody (TRAb) measurement (85·6%) and thyroid ultrasound (70·6%) to confirm aetiology, while isotopic studies were selected by 37·7%. Antithyroid drug (ATD) therapy was the …

medicine.medical_specialtyExacerbationEndocrinology Diabetes and MetabolismGraves' diseaseThyrotropin030209 endocrinology & metabolismTrabDisease03 medical and health sciences0302 clinical medicineEndocrinologyAntithyroid AgentsPregnancySurveys and QuestionnairesInternal medicinemedicineHumansPractice Patterns Physicians'AutoantibodiesPregnancyMethimazolebusiness.industryThyroidReceptors Thyrotropinmedicine.diseaseGraves DiseaseEuropePregnancy ComplicationsThyroxineEndocrinologymedicine.anatomical_structurePropylthiouracil030220 oncology & carcinogenesisNorth AmericaEtiologyFemalePropylthiouracilbusinessmedicine.drugClinical Endocrinology
researchProduct

2018

Objective: Acromegalic patients display a distinct neuropsychological profile and suffer from chronic physical complaints. We aimed to investigate in more detail these aspects in acromegalic patients, dependent on influencing factors like disease activity, age, sex, chronic medication, surgery, pituitary radiation, pituitary insufficiency and comorbidities. Design: Cross sectional, multicentric. Methods: 129 patients (M/W 65/64, 58.3 ± 12.7 years, 53/76 with active/controlled disease). Acromegalic patients completed the following inventories: NEO-FFI, IIP-D, and the Giessen Complaints List (GBB-24), after written informed consent. Age, sex, IGF-1 concentrations, comorbidities, treatment mod…

medicine.medical_specialtyExtraversion and introversionbusiness.industryEndocrinology Diabetes and MetabolismNeuropsychology030209 endocrinology & metabolismDiseasemedicine.diseaseComorbidityNeuroticism03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineAcromegalymedicinePermissiveBig Five personality traitsbusinessFrontiers in Endocrinology
researchProduct

Rapid Regression of Exudative Maculopathy in Idiopathic Retinitis, Vasculitis, Aneurysms and Neuroretinitis Syndrome after Intravitreal Ranibizumab

2012

The idiopathic retinitis, vasculitis, aneurysms and neuroretinitis syndrome is a rare retinal vascular disorder characterized by multiple leaking aneurysmal dilations, retinal vasculitis, neuroretinitis and peripheral vascular ischemia. Visual loss mainly occurs due to the development of retinal neovascularization and/or exudative maculopathy. Although the treatment of choice has not yet been established, retinal photocoagulation seems to be the best option to control the disease and to prevent its progression. Herein, we report a case of idiopathic retinitis, vasculitis, aneurysms and neuroretinitis syndrome with both retinal neovascularization and macular exudation successfully managed wi…

medicine.medical_specialtyExudative maculopathyRapid regressiongenetic structuresbusiness.industryRetinal vasculitisPublished online: August 2012medicine.diseaseeye diseasesOphthalmologylcsh:Ophthalmologylcsh:RE1-994OphthalmologyRanibizumabmedicineIdiopathic retinitisIdiopathic retinitis vasculitis aneurysms and neuroretinitis syndromeRetinal Vascular DisorderRanibizumabIntravitreal ranibizumabbusinessVasculitisExudative maculopathymedicine.drugCase Reports in Ophthalmology
researchProduct

Improvement of asymmetric thyroid eye disease with teprotumumab

2021

PurposeTeprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid eye disease (TED) in recent clinical trials. Given its specificity, we expect it to demonstrate greater efficacy on the worse affected orbit, in patients with asymmetric TED. Herein, we investigate the differential impact of teprotumumab on the orbits of such patients.MethodsIn this pooled analysis of patients who were enrolled in the recent phase 2 (NCT01868997) and phase 3 (NCT03298867) trials, all patients with asymmetric TED (difference in exophthalmometry of ≥3 mm) were screened for eligibility. The primary outcomes of the trials, prop…

medicine.medical_specialtyEye disease030209 endocrinology & metabolismAntibodies Monoclonal HumanizedPlacebo03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineInternal medicineBlocking antibodyDiplopiamedicineExophthalmosHumansDifferential impactDiplopiabusiness.industryThyroidmedicine.diseaseeye diseasesSensory SystemsGraves OphthalmopathyClinical trialOphthalmologyPooled analysismedicine.anatomical_structure030221 ophthalmology & optometrymedicine.symptombusinessBritish Journal of Ophthalmology
researchProduct